FLEURY S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.44 BRL | +3.07% |
|
-2.63% | -19.96% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 7.79B 1.52B | Sales 2025 * | 8.34B 1.63B | Capitalization | 8.04B 1.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 637M 124M | Net income 2025 * | 786M 153M | EV / Sales 2024 * | 1.49 x |
| Net Debt 2024 * | 3.58B 698M | Net Debt 2025 * | 3.24B 632M | EV / Sales 2025 * | 1.35 x |
| P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
10.4
x | Employees | 27,300 |
| Yield 2024 * |
2.91% | Yield 2025 * |
5.26% | Free-Float | 43.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fleury S.A.
More press releases
| 1 day | -1.21% | ||
| 1 week | +1.30% | ||
| Current month | +1.86% | ||
| 1 month | -1.07% | ||
| 3 months | -8.39% | ||
| 6 months | -10.17% | ||
| Current year | -18.24% |
1 week
14.58
15.07
1 month
13.6915.07
Current year
13.6918.08
1 year
13.6918.96
3 years
12.8926.55
5 years
12.8932.47
10 years
6.1032.47
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 00-12-31 | |
| Director of Finance/CFO | 63 | 21-07-22 | |
| Chief Tech/Sci/R&D Officer | 48 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | - | |
| Director/Board Member | 78 | 13-04-08 | |
João Teixeira
BRD | Director/Board Member | 58 | 21-04-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.24% | 0 M€ | -1.08% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 0 M€ | +4.02% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 14.44 | +3.07% | 1 377 000 |
| 24-05-09 | 14.75 | -1.21% | 2,809,900 |
| 24-05-08 | 14.93 | +0.07% | 1,468,700 |
| 24-05-07 | 14.92 | +0.20% | 2,209,000 |
| 24-05-06 | 14.89 | +0.40% | 2,051,600 |
Delayed Quote Sao Paulo, May 09, 2024 at 04:07 pm EDT
More quotes
Fleury S.A. specializes in clinical diagnosis, treatment and analysis services.
At the end of 2018, the group operated a network of 187 patient care centers and 23 hospital centers under Fleury, Weinmann, Clínica Felipe Mattoso, a +, Labs a + and Diagnoson a + brands.
Calendar
10:00am
- Q1 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
14.75
BRL
Average target price
19.6
BRL
Spread / Average Target
+32.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.24% | 1.58B | |
| -16.58% | 8.44B | |
| +54.07% | 3.96B | |
| -37.54% | 2.52B | |
| -10.51% | 2.44B | |
| -8.91% | 2.22B | |
| -4.20% | 1.98B | |
| -36.41% | 1.3B | |
| +2.19% | 1.05B | |
| -32.43% | 902M |
- Stock Market
- Equities
- FLRY3 Stock